Literature DB >> 33553227

Yokukansankachimpihange Is Useful to Treat Behavioral/Psychological Symptoms of Dementia.

Eiichi Katsumoto1,2, Toru Ishida1,3, Kenji Kinoshita1,4, Miho Shimizu1,5, Toshihito Tsutsumi1,6, Yoko Nagai1,7, Masakazu Nishimura1,8, Toshio Yokouchi1,9, Yasushi Yoshida1,10.   

Abstract

Yokukansankachimpihange is a Japanese herbal medicine reported to benefit anxiety and sleep disorders, and it has recently been introduced to treat behavioral and psychological symptoms of dementia. There are no multicenter studies of its effectiveness regarding dementia in Japan, and this study's main objective was to clarify the effects of Yokukansankachimpihange on behavioral and psychological symptoms of dementia in a sample of patients from multiple healthcare centers. Nine facilities affiliated with Osaka Association of Psychiatric Clinics participated in November 2013 through April 2015 and provided 32 Alzheimer's disease patients to whom Yokukansankachimpihange was orally administered for 8 weeks. During the study, the patients continued their regular medication regimens. Behavioral and psychological symptoms of dementia (Behavioral Pathology in Alzheimer's Disease Rating Scale [Behave-AD]), core symptoms [Mini-Mental State Examination (MMSE)], activities of daily living [Nishimura Activity of Daily Living Scale (N-ADL)], and gastrointestinal symptoms (nausea/vomiting, loss of appetite, gastric discomfort, constipation, and diarrhea) were measured at baseline, after 4 weeks of treatment and after 8 weeks of treatment. Yokukansankachimpihange was orally administered at a dosage of 7.5 g twice daily before or between meals for 8 weeks. The Behave-AD mean score significantly improved after 8 weeks of treatment. There were no significant changes in MMSE, N-ADL, or gastrointestinal symptoms; however, decreased gastrointestinal scores were observed after 8 weeks. There were no side effects related to Yokukansankachinpihange. Pharmaceutical treatments are important for treating behavioral and psychological symptoms of dementia, and this study confirmed Yokukansankachimpihange's efficacy for treating Alzheimer's disease. Because the aggressiveness and sleep disorder components of the Behave-AD construct were the symptoms most improved and those symptoms are known to significantly burden dementia patients' caregivers, Yokukansankachimpihange's efficacy might indirectly relieve these caregivers' burden of care.
Copyright © 2021 Katsumoto, Ishida, Kinoshita, Shimizu, Tsutsumi, Nagai, Nishimura, Yokouchi and Yoshida.

Entities:  

Keywords:  Alzheimer's disease; behavioral dementia symptoms; dementia; insomnia; multi-center research; psychological dementia symptoms

Year:  2021        PMID: 33553227      PMCID: PMC7858647          DOI: 10.3389/fnut.2020.529390

Source DB:  PubMed          Journal:  Front Nutr        ISSN: 2296-861X


  4 in total

Review 1.  Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yuki Matsuda; Taro Kishi; Hiroto Shibayama; Nakao Iwata
Journal:  Hum Psychopharmacol       Date:  2013-01       Impact factor: 1.672

2.  Yokukansan Enhances Pentobarbital-Induced Sleep in Socially Isolated Mice: Possible Involvement of GABA(A) - Benzodiazepine Receptor Complex.

Authors:  Nobuaki Egashira; Ai Nogami; Katsunori Iwasaki; Ayumi Ishibashi; Naoki Uchida; Kotaro Takasaki; Kenichi Mishima; Ryoji Nishimura; Ryozo Oishi; Michihiro Fujiwara
Journal:  J Pharmacol Sci       Date:  2011-06-18       Impact factor: 3.337

3.  Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism.

Authors:  Hiroshi Takeda; Chiharu Sadakane; Tomohisa Hattori; Takehiko Katsurada; Tatsuya Ohkawara; Koichi Nagai; Masahiro Asaka
Journal:  Gastroenterology       Date:  2008-02-29       Impact factor: 22.682

4.  Antianxiety-like effects of Chimpi (dried citrus peels) in the elevated open-platform test.

Authors:  Aya Ito; Noriyuki Shin; Takashi Tsuchida; Toshiki Okubo; Hisayoshi Norimoto
Journal:  Molecules       Date:  2013-08-20       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.